2 results
Approved WMOCompleted
The study is intended to provide insight into the clinical feasibility of the Exilis* system as a therapy for obesity, including:* Providing initial human safety data on the Exilis* system, * Gaining an understanding of how to individually titrate…
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…